Open Payments

BOSTON MEDICAL CENTER CORPORATION

Type
Non-covered entity
Where
SOUTH BOSTON, MA
Received
$739,068 in 23 records, 2021 to 2025 ($0 general, $739,068 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025Research payment8$7,147
2024Research payment11$700,527
2023Research payment2$18,141
2021Research payment2$13,252

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC4$617,9532024
Novartis Pharmaceuticals Corporation4$83,8862023–2024
Inari Medical, Inc.4$15,5282024
Neurocrine BioSciences, Inc.2$13,2522021
GlaxoSmithKline, LLC.7$6,9852025
Alexion Pharmaceuticals, Inc.1$1,3002023
ViiV Healthcare Company1$1622025

By nature of payment

NatureRecordsAmount
Research payment23$739,068

Records

DateCompanyAmountNatureFormProductStudyYear
2025-07-21GlaxoSmithKline, LLC.$550Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2025
2025-05-02GlaxoSmithKline, LLC.$2,730Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2025
2025-03-21GlaxoSmithKline, LLC.$1,300Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2025
2025-03-21GlaxoSmithKline, LLC.$1,300Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2025
2025-03-21GlaxoSmithKline, LLC.$812Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2025
2025-03-21GlaxoSmithKline, LLC.$130Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2025
2025-02-07ViiV Healthcare Company$162Research paymentCash or cash equivalentA PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E2025
2025-02-03GlaxoSmithKline, LLC.$162Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P2025
2024-12-17Novartis Pharmaceuticals Corporation$29,041Research paymentCash or cash equivalentA Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safet2024
2024-10-21Merck Sharp & Dohme LLC$232,883Research paymentCash or cash equivalentPNEUMOVAX 23 Biological, VACCINEImmunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients2024
2024-10-21Merck Sharp & Dohme LLC$95,699Research paymentCash or cash equivalentSTUDY NAME#Addressing disparities in influenza vaccination# Develop and pilot test a novel methodology grounded in the C2024
2024-08-19Inari Medical, Inc.$3,055Research paymentCash or cash equivalentLIMFLOW SYSTEM Device, CLTIPROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia2024
2024-08-19Inari Medical, Inc.$3,055Research paymentCash or cash equivalentLIMFLOW SYSTEM Device, CLTIPROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia2024
2024-08-05Merck Sharp & Dohme LLC$201,519Research paymentCash or cash equivalentGARDASIL 9 Biological, VACCINEAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen over a Fo2024
2024-07-16Novartis Pharmaceuticals Corporation$27,303Research paymentCash or cash equivalentFabhalta Drug, ImmunologyA Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of2024
2024-04-24Inari Medical, Inc.$8,043Research paymentCash or cash equivalentLIMFLOW SYSTEM Device, CLTIPROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia2024
2024-04-23Inari Medical, Inc.$1,375Research paymentCash or cash equivalentLIMFLOW SYSTEM Device, CLTIPROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia2024
2024-03-12Novartis Pharmaceuticals Corporation$10,699Research paymentCash or cash equivalentADAKVEO Drug, HematologyA phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses 2024
2024-03-04Merck Sharp & Dohme LLC$87,850Research paymentCash or cash equivalentSTUDY NAME#Molecular characterization of virulence factors in an in vitro model of Respiratory Synctial Virus and Strept2024
2023-11-29Alexion Pharmaceuticals, Inc.$1,300Research paymentCash or cash equivalentA Phase 2a, Randomized, Open Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients2023
2023-03-13Novartis Pharmaceuticals Corporation$16,841Research paymentCash or cash equivalentADAKVEO Drug, HematologyA phase III, Multicenter, Randomized, Placebo controlled, Double-blind Study to Assess Efficacy and Safety of Two Doses 2023
2021-07-16Neurocrine BioSciences, Inc.$10,825Research paymentCash or cash equivalentOPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT2021
2021-07-16Neurocrine BioSciences, Inc.$2,427Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBEN2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In Massachusetts; placed by its state only.

MeasureState
Massachusetts
Population B010037,044,056
Population, 2020 census P17,029,917
Median age B0100240.0
Under 18 B0100119.4%
65 and over B0100117.9%
Households B110012,785,042
Foreign born B0500218.0%
Median household income B19013$103,960
Median family income B19113$131,675
Per capita income B19301$57,897
Poverty rate B1700110.0%
Unemployment rate B230255.2%
Civilian labor force B230253,911,446
Mean commute (minutes) B0801329.1
Bachelor's degree or higher B1500347.3%
Housing units B250013,030,406
Owner-occupied B2500362.5%
Renters B2500337.5%
Median home value B25077$562,100
Median gross rent B25064$1,762
White, not Hispanic B0300266.6%
Black B030026.4%
Hispanic or Latino B0300213.3%
Asian B030027.3%
American Indian and Alaska Native B030020.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.